相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status
Dominik P. Modest et al.
ANTI-CANCER DRUGS (2011)
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
N. Knijn et al.
BRITISH JOURNAL OF CANCER (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer
Jin Hyun Park et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer
Jeanne Tie et al.
CLINICAL CANCER RESEARCH (2011)
Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer
F. Aubin et al.
Current Oncology (2011)
Heterogeneity of KRAS Status May Explain the Subset of Discordant KRAS Status Between Primary and Metastatic Colorectal Cancer
Toshiaki Watanabe et al.
DISEASES OF THE COLON & RECTUM (2011)
Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
Gordon Hutchins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer
Alenka Licar et al.
MEDICAL ONCOLOGY (2011)
Different characteristics and prognostic impact of deep-vein thrombosis/pulmonary embolism and intraabdominal venous thrombosis in colorectal cancer patients
Seyoun Choi et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2008
Kyu-Won Jung et al.
CANCER RESEARCH AND TREATMENT (2011)
KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases
Garrett M. Nash et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
Stephan E. Baldus et al.
CLINICAL CANCER RESEARCH (2010)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
KRAS Mutation Testing in Colorectal Cancer
Thomas P. Plesec et al.
ADVANCES IN ANATOMIC PATHOLOGY (2009)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
BRAF Mutation in Metastatic Colorectal Cancer.
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis
Paloma Cejas et al.
PLOS ONE (2009)
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
S. Gattenloehner et al.
JOURNAL OF ONCOLOGY (2009)
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
Minaxi Jhawer et al.
CANCER RESEARCH (2008)
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy
Marie-Christine Etienne-Grimaldi et al.
CLINICAL CANCER RESEARCH (2008)
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer
Salvatore Artale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
Daniele Santini et al.
ONCOLOGIST (2008)
Expanding criteria for resectability of colorectal liver metastases
Timothy M. Pawlik et al.
ONCOLOGIST (2008)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
C. Oliveira et al.
ONCOGENE (2007)
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases
Eric Van Cutsem et al.
EUROPEAN JOURNAL OF CANCER (2006)
Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations
I Albanese et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
分享论文
